Company profile: ImmunoGen
1.1 - Company Overview
Company description
- Provider of antibody-based anticancer therapeutics using TAP, ELAHERE for platinum-resistant ovarian cancer; investigational IMGN632 for acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm; mirvetuximab soravtansine (monotherapy, with bevacizumab or carboplatin) for platinum-sensitive ovarian cancers; and IMGN151 for recurrent endometrial and high-grade serous epithelial ovarian, primary peritoneal, or fallopian tube cancers.
Products and services
- ELAHERE (mirvetuximab soravtansine-gynx): An ADC-based therapy targeting platinum-resistant ovarian cancer, engineered using Targeted Antibody Payload to deliver a potent cytotoxic agent directly via antibody-mediated targeting
- IMGN151: A TAP-enabled investigational therapy for recurrent endometrial cancer and high-grade serous epithelial ovarian, primary peritoneal, or fallopian tube cancers, utilizing antibodies to ferry cytotoxic payloads
- IMGN632 (Pivekimab Sunirine): An investigational-stage antibody-based therapeutic for CD123-positive acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm, leveraging TAP technology to deliver a potent cytotoxic agent to malignant cells
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to ImmunoGen
Gradalis
HQ: United States
Website
- Description: Provider of personalized cancer immunotherapy leveraging patients' own genetically modified tumor cells to enhance immune recognition and killing through its Vigil platform, and of clinical trials evaluating the safety and efficacy of Vigil across cancer types, including ovarian cancer and Ewing’s sarcoma.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Gradalis company profile →
Luminist Labs
HQ: United States
Website
- Description: Provider of a rapidly scalable, low-cost diagnostic platform for early detection and diagnosis of liver disease and screening for many diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Luminist Labs company profile →
Intera Oncology
HQ: United States
Website
- Description: Provider of hepatic artery infusion (HAI) therapy and liver-directed chemotherapy delivery for colorectal cancer and cholangiocarcinoma patients, offering the Intera 3000 HAI pump, Cerona Therapeutics Floxuridine for Injection, USP, and related products (heparinized saline, saline, bacteriostatic water); acquired Oncology/Neuromodulation Drug Delivery products from Johnson & Johnson.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Intera Oncology company profile →
Cellestia
HQ: Switzerland
Website
- Description: Provider of clinical-stage R&D therapies to control and modulate pathogenic gene expression via selective inhibition of transcription factors in the cell nucleus. Lead candidate CB-103 targets the CSL-NOTCH complex and is in Phase 2 for various cancers and GvHD, showing efficacy in multi-drug resistant cancers and autoimmune diseases. Pipeline includes preclinical assets for psoriasis, Sjogren’s, SLE, IBD and giant cell arteritis.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cellestia company profile →
Medite Cancer Diagnostics
HQ: United States
Website
- Description: Provider of development, manufacture, and distribution as a mid-sized industrial corporation.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Medite Cancer Diagnostics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for ImmunoGen
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to ImmunoGen
2.2 - Growth funds investing in similar companies to ImmunoGen
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for ImmunoGen
4.2 - Public trading comparable groups for ImmunoGen
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →